Cellectis in supply and license deal with Takara Bio for RetroNectin

French biotech company Cellectis (Euronext Paris: ALCLS) has entered into a supply and license agreement with Japan’s Takara Bio (TYO: 4974) for recombinant human fibronectin fragment RetroNectin.

Access to Takara’s RetroNectin will secure Cellectis’ manufacturing processes and expand the company’s UCART production capabilities. Under the terms of the agreement, RetroNectin, which is used for cell engineering, may be applied in the production of both R&D- and GMP-grade Cellectis’ UCART product candidates. Financial terms of the accord are not disclosed.

In 2014 Cellectis sold its Swedish subsidiary Cellectis AB to Takara Bio, in order to concentrate its activities in the field of oncology through the development of chimeric antigen receptor T-cell (CAR-T) immunotherapy products generated through its allogeneic CAR-T platform (The Pharma Letter July 30, 2014).